Safety and Tolerability of Single and Multiple Doses of SoftOx Biofilm Eradicator (SBE) in Chronic Leg Wounds

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 19, 2021

Primary Completion Date

August 19, 2022

Study Completion Date

August 19, 2022

Conditions
Chronic Leg UlcerVenous Leg Ulcer
Interventions
DRUG

SoftOx Biofilm Eradicator (Groups 1 to 7)

SBE is a water-based formulation containing hypochlorous acid (HOCl) at concentrations of 500-1000 µg/mL and acetic acid (HAc) at concentrations of 1-3 %. Both active ingredients are naturally occurring molecules and have a long history of safe use in medicinal products and in solutions approved as medical devices. Both molecules, exhibit broad-spectrum antimicrobial activity at the concentrations present in SBE. The antimicrobial effect of HOCl is rapid and powerful by acting on and disrupting the function of key microbial molecules such as proteins, lipids, and nucleic acids, while remaining safe to mammalian cells and not promoting the emergence of new resistant microbes. Moreover, HOCl is active against biofilms, and some studies suggest that HOCl may also increase oxygenation of the wound site leading to improved healing.

DEVICE

Sterile isotonic saline (Groups 1 to 4)

Sterile isotonic saline was used as placebo because it is part of standard of care, used as an irrigation solution at dressing change and has the same appearance as SBE

Trial Locations (1)

2400

Bispebjerg University Hospital, Copenhagen

All Listed Sponsors
lead

SoftOx Solutions AS

INDUSTRY

NCT05710094 - Safety and Tolerability of Single and Multiple Doses of SoftOx Biofilm Eradicator (SBE) in Chronic Leg Wounds | Biotech Hunter | Biotech Hunter